Biosimulation Market Size, Share & Trend Analysis Report By Product (Software, Services), By Application (Drug, Development, Discovery), By End-use, By Region, Vendor Landscape, And Segment Forecasts, 2018 - 2024

Published: May, 2018 | Pages: 84 | Publisher: Grand View Research
Industry: Healthcare | Report Format: Electronic (PDF)

The global biosimulation market size is expected to reach USD 3.77 billion by 2024, according to a new report by Grand View Research, Inc., registering a CAGR of 15.4% during the forecast period. Soaring need for advanced generation therapeutics owing to growing prevalence of chronic diseases, such as cancer and diabetes, is stoking the growth of the biosimulation market.

Moreover, widening base of geriatric population worldwide is playing an imperative role in the growth of the market. Aged people are highly susceptible to chronic diseases, which is augmenting the need for highly efficacious drugs. In addition, growing number of drug resistance cases, high drug relapse rate, and limited availability drugs to treat diseases such as AIDS are leading to high clinical urgency for adoption of biosimulation in applications such as drug development and drug discovery.

Surging demand for biosimulation software and services can also be attributed to their higher cost efficiency. This cost efficiency is a result of ability to predict toxicity, adverse reactions, and efficacy of investigational drugs during early stages of product development, thus limiting the probability of drug relapse & adverse events at later stages.

Further Key Findings from the Report Suggest:

• Software accounted for the largest share of the product segment in 2015 owing to growing adoption in personalized medicine resulting in improved patient outcomes

• The services segment is expected to exhibit growth at a significant CAGR as a consequence of rising inclination of the big pharmaceutical companies to outsource their biosimulation process so as to reduce the overall cost

• The drug discovery segment is predicted to witness a lucrative CAGR throughout the forecast period owing to elimination of probable drug failures and prediction of unfavorable drug interactions

• Drug development accounted for the largest share owing to growing usage of in silico software by major pharmaceutical & biotechnology companies for increased drug efficacy of their existing products by identification and evaluation of optimal synergistic combinations & dosage forms

• In 2015, the pharmaceutical and biotechnology companies held a substantial share owing to growing efforts to develop better treatment options at a cheaper and faster rate through in silico biology models

• Academic research institutes are anticipated to grow at consistent rate owing to presence of various academic research groups involved in complex biological systems studies that use computer models, such as by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

• In 2015, North America accounted for majority share of overall market as a result of increased usage of in silico models by regulatory authorities to ensure patient safety

• Asia Pacific is predicted to spearhead the market as a consequence of increasing outsourcing research activities across this region

• Key players are deploying collaborative strategies and expansion of product portfolio to capture a large share. For instance, in April 2016, Simulation Plus, Inc. introduced DDDPlus Version 5.0, an in-vitro dissolution experiment software that helps researchers in study of different drug dosage forms

Table of Content

Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
1.3. List of Data Sources
Chapter 2. Executive Summary
Chapter 3. Market Snapshot
Chapter 4. Market Variables, Trends & Scope
4.1. Market segmentation & scope
4.2. Market Driver Analysis
4.3. Market Restraint Analysis
4.4. Penetration & growth prospect mapping
4.5. Biosimulation - SWOT Analysis, By Factor (political & legal, economic and technological)
4.6. Industry Analysis - Porter's
Chapter 5. Market Categorization 1: Product Estimates & Trend Analysis
5.1. Biosimulation market: Product movement analysis
5.2. Software
5.2.1. Software Market Estimates and Forecasts, 2013 - 2024 (USD Million)
5.3. Services
5.3.1. Services Market Estimates and Forecasts, 2013 - 2024 (USD Million)
5.3.2. In-house Services
5.3.2.1. In-house Services Market Estimates and Forecasts, 2013 - 2024 (USD Million)
5.3.3. Contract Services
5.3.3.1. Contract Services Market Estimates and Forecasts, 2013 - 2024 (USD Million)
Chapter 6. Market Categorization 2: Application Estimates & Trend Analysis
6.1. Biosimulation market: Application movement analysis
6.2. Drug Development
6.2.1. Drug Development Market Estimates and Forecasts, 2013 - 2024 (USD Million)
6.3. Drug Discovery
6.3.1. Drug Discovery Market Estimates and Forecasts, 2013 - 2024 (USD Million)
6.4. Others
6.4.1. Others Market Estimates and Forecasts, 2013 - 2024 (USD Million)
Chapter 7. Market Categorization 3: End-use Estimates & Trend Analysis
7.1. Biosimulation market: Application movement analysis
7.2. Pharmaceutical & Biotechnology Companies
7.2.1. Pharmaceutical &Biotechnology Companies Market Estimates and Forecasts, 2013 - 2024 (USD Million)
7.3. CROs
7.3.1. CROs Market Estimates and Forecasts, 2013 - 2024 (USD Million)
7.4. Regulatory Authorities
7.4.1. Regulatory Authorities Market Estimates and Forecasts, 2013 - 2024 (USD Million)
7.5. Academic Research Institutions
7.5.1. Academic Research Institutions Market Estimates and Forecasts, 2013 - 2024 (USD Million)
Chapter 8. Market Categorization 3: Regional Estimates & Trend Analysis, By Type & Application
8.1. Biosimulation Market Share by Region, 2015 & 2024
8.2. North America
8.2.1. North America Market Estimates and Forecasts, By Product, 2013 - 2024 (USD Million)
8.2.1.1. U.S. Market Estimates and Forecasts
8.2.1.2. Canada Market Estimates and Forecasts
8.2.2. North America Market Estimates and Forecasts, By Application, 2013 - 2024 (USD Million)
8.2.2.1. U.S. Market Estimates and Forecasts
8.2.2.2. Canada Market Estimates and Forecasts
8.2.3. North America Market Estimates and Forecasts, By End-use, 2013 - 2024 (USD Million)
8.2.3.1. U.S. Market Estimates and Forecasts
8.2.3.2. Canada Market Estimates and Forecasts
8.3. Europe
8.3.1. Europe Market Estimates and Forecasts, By Product, 2013 - 2024 (USD Million)
8.3.1.1. UK Market Estimates and Forecasts
8.3.1.2. Germany Market Estimates and Forecasts
8.3.2. Europe Market Estimates and Forecasts, By Application, 2013 - 2024 (USD Million)
8.3.2.1. UK Market Estimates and Forecasts
8.3.2.2. Germany Market Estimates and Forecasts
8.3.3. Europe Market Estimates and Forecasts, By End-use, 2013 - 2024 (USD Million)
8.3.3.1. UK Market Estimates and Forecasts
8.3.3.2. Germany Market Estimates and Forecasts
8.4. Asia Pacific
8.4.1. Asia Pacific Market Estimates and Forecasts, By Product, 2013 - 2024 (USD Million)
8.4.1.1. Japan Market Estimates and Forecasts
8.4.1.2. China Market Estimates and Forecasts
8.4.1.3. India Market Estimates and Forecasts
8.4.2. Asia Pacific Market Estimates and Forecasts, By Application, 2013 - 2024 (USD Million)
8.4.2.1. Japan Market Estimates and Forecasts
8.4.2.2. China Market Estimates and Forecasts
8.4.2.3. India Market Estimates and Forecasts
8.4.3. Asia Pacific Market Estimates and Forecasts, By End-use, 2013 - 2024 (USD Million)
8.4.3.1. Japan Market Estimates and Forecasts
8.4.3.2. China Market Estimates and Forecasts
8.4.3.3. India Market Estimates and Forecasts
8.5. Latin America
8.5.1. Latin America Market Estimates and Forecasts, By Product, 2013 - 2024 (USD Million)
8.5.1.1. Brazil Market Estimates and Forecasts
8.5.1.2. Mexico Market Estimates and Forecasts
8.5.2. Latin America Market Estimates and Forecasts, By Application, 2013 - 2024 (USD Million)
8.5.2.1. Brazil Market Estimates and Forecasts
8.5.2.2. Mexico Market Estimates and Forecasts
8.5.3. Latin America Market Estimates and Forecasts, By End-use, 2013 - 2024 (USD Million)
8.5.3.1. Brazil Market Estimates and Forecasts
8.5.3.2. Mexico Market Estimates and Forecasts
8.6. MEA
8.6.1. MEA Market Estimates and Forecasts, By Product, 2013 - 2024 (USD Million)
8.6.1.1. South Africa Market Estimates and Forecasts
8.6.2. MEA Market Estimates and Forecasts, By Application, 2013 - 2024 (USD Million)
8.6.2.1. South Africa Market Estimates and Forecasts
8.6.3. MEA Market Estimates and Forecasts, By End-use, 2013 - 2024 (USD Million)
8.6.3.1. South Africa Market Estimates and Forecasts
Chapter 9. Competitive Landscape
9.1. Strategy framework
9.2. Market participation categorization
9.3. Company Profiles
9.3.1. Certara USA, Inc.
9.3.1.1. Company Overview
9.3.1.2. Financial Performance
9.3.1.3. Product Benchmarking
9.3.1.4. Strategic Initiatives
9.3.2. Simulation Plus, Inc.
9.3.2.1. Company Overview
9.3.2.2. Financial Performance
9.3.2.3. Product Benchmarking
9.3.2.4. Strategic Initiatives
9.3.3. Dassault Systems SA
9.3.3.1. Company Overview
9.3.3.2. Financial Performance
9.3.3.3. Product Benchmarking
9.3.3.4. Strategic Initiatives
9.3.4. Schrodinger, Inc.
9.3.4.1. Company Overview
9.3.4.2. Financial Performance
9.3.4.3. Product Benchmarking
9.3.4.4. Strategic Initiatives
9.3.5. Advanced Chemistry Development, Inc.
9.3.5.1. Company Overview
9.3.5.2. Financial Performance
9.3.5.3. Product Benchmarking
9.3.5.4. Strategic Initiatives
9.3.6. Chemical Computing Group, Inc.
9.3.6.1. Company Overview
9.3.6.2. Financial Performance
9.3.6.3. Product Benchmarking
9.3.6.4. Strategic Initiatives
9.3.7. Physiomics PLC
9.3.7.1. Company Overview
9.3.7.2. Financial Performance
9.3.7.3. Product Benchmarking
9.3.7.4. Strategic Initiatives
9.3.8. Entelos, Inc.
9.3.8.1. Company Overview
9.3.8.2. Financial Performance
9.3.8.3. Product Benchmarking
9.3.8.4. Strategic Initiatives
9.3.9. Rhenovia Pharma Ltd.
9.3.9.1. Company Overview
9.3.9.2. Financial Performance
9.3.9.3. Product Benchmarking
9.3.9.4. Strategic Initiatives
9.3.10. Genedata AG
9.3.10.1. Company Overview
9.3.10.2. Financial Performance
9.3.10.3. Product Benchmarking
9.3.10.4. Strategic Initiatives
9.3.11. Leadscope, Inc.
9.3.11.1. Company Overview
9.3.11.2. Financial Performance
9.3.11.3. Product Benchmarking
9.3.11.4. Strategic Initiatives
9.3.12. Evidera, Inc.
9.3.12.1. Company Overview
9.3.12.2. Financial Performance
9.3.12.3. Product Benchmarking
9.3.12.4. Strategic Initiatives
9.3.13. Insilico Biotechnology AG
9.3.13.1. Company Overview
9.3.13.2. Financial Performance
9.3.13.3. Product Benchmarking
9.3.13.4. Strategic Initiatives
9.3.14. LeadInvent Technologies Pvt. Ltd.
9.3.14.1. Company Overview
9.3.14.2. Financial Performance
9.3.14.3. Product Benchmarking
9.3.14.4. Strategic Initiatives
9.3.15. InhibOx Ltd.
9.3.15.1. Company Overview
9.3.15.2. Financial Performance
9.3.15.3. Product Benchmarking
9.3.15.4. Strategic Initiatives

List of Tables

TABLE 1 North America biosimulation market, by product, 2013 - 2024 (USD Million)
TABLE 2 North America biosimulation software market, by type, 2013 - 2024 (USD Million)
TABLE 3 North America biosimulation services market, by type, 2013 - 2024 (USD Million)
TABLE 4 North America biosimulation market, by application, 2013 - 2024 (USD Million)
TABLE 5 North America biosimulation market, by end-use, 2013 - 2024 (USD Million)
TABLE 6 U.S. biosimulation market, by product, 2013 - 2024 (USD Million)
TABLE 7 U.S. biosimulation software market, by type, 2013 - 2024 (USD Million)
TABLE 8 U.S. biosimulation services market, by type, 2013 - 2024 (USD Million)
TABLE 9 U.S. biosimulation market, by application, 2013 - 2024 (USD Million)
TABLE 10 U.S. biosimulation market, by end-use, 2013 - 2024 (USD Million)
TABLE 11 Canada biosimulation market, by product, 2013 - 2024 (USD Million)
TABLE 12 Canada biosimulation software market, by type, 2013 - 2024 (USD Million)
TABLE 13 Canada biosimulation services market, by type, 2013 - 2024 (USD Million)
TABLE 14 Canada biosimulation market, by application, 2013 - 2024 (USD Million)
TABLE 15 Canada biosimulation market, by end-use, 2013 - 2024 (USD Million)
TABLE 16 Europe biosimulation market, by product, 2013 - 2024 (USD Million)
TABLE 17 Europe biosimulation software market, by type, 2013 - 2024 (USD Million)
TABLE 18 Europe biosimulation services market, by type, 2013 - 2024 (USD Million)
TABLE 19 Europe biosimulation market, by application, 2013 - 2024 (USD Million)
TABLE 20 Europe biosimulation market, by end-use, 2013 - 2024 (USD Million)
TABLE 21 Germany biosimulation market, by product, 2013 - 2024 (USD Million)
TABLE 22 Germany biosimulation software market, by type, 2013 - 2024 (USD Million)
TABLE 23 Germany biosimulation services market, by type, 2013 - 2024 (USD Million)
TABLE 24 Germany biosimulation market, by application, 2013 - 2024 (USD Million)
TABLE 25 Germany biosimulation market, by end-use, 2013 - 2024 (USD Million)
TABLE 26 UK biosimulation market, by product, 2013 - 2024 (USD Million)
TABLE 27 UK biosimulation software market, by type, 2013 - 2024 (USD Million)
TABLE 28 UK biosimulation services market, by type, 2013 - 2024 (USD Million)
TABLE 29 UK biosimulation market, by application, 2013 - 2024 (USD Million)
TABLE 30 UK biosimulation market, by end-use, 2013 - 2024 (USD Million)
TABLE 31 Asia Pacific biosimulation market, by product, 2013 - 2024 (USD Million)
TABLE 32 Asia Pacific biosimulation software market, by type, 2013 - 2024 (USD Million)
TABLE 33 Asia Pacific biosimulation services market, by type, 2013 - 2024 (USD Million)
TABLE 34 Asia Pacific biosimulation market, by application, 2013 - 2024 (USD Million)
TABLE 35 Asia Pacific biosimulation market, by end-use, 2013 - 2024 (USD Million)
TABLE 36 Japan biosimulation market, by product, 2013 - 2024 (USD Million)
TABLE 37 Japan biosimulation software market, by type, 2013 - 2024 (USD Million)
TABLE 38 Japan biosimulation services market, by type, 2013 - 2024 (USD Million)
TABLE 39 Japan biosimulation market, by application, 2013 - 2024 (USD Million)
TABLE 40 Japan biosimulation market, by end-use, 2013 - 2024 (USD Million)
TABLE 41 China biosimulation market, by product, 2013 - 2024 (USD Million)
TABLE 42 China biosimulation software market, by type, 2013 - 2024 (USD Million)
TABLE 43 China biosimulation services market, by type, 2013 - 2024 (USD Million)
TABLE 44 China biosimulation market, by application, 2013 - 2024 (USD Million)
TABLE 45 China biosimulation market, by end-use, 2013 - 2024 (USD Million)
TABLE 46 India biosimulation market, by product, 2013 - 2024 (USD Million)
TABLE 47 India biosimulation software market, by type, 2013 - 2024 (USD Million)
TABLE 48 India biosimulation services market, by type, 2013 - 2024 (USD Million)
TABLE 49 India biosimulation market, by application, 2013 - 2024 (USD Million)
TABLE 50 India biosimulation market, by end-use, 2013 - 2024 (USD Million)
TABLE 51 Latin America biosimulation market, by product, 2013 - 2024 (USD Million)
TABLE 52 Latin America biosimulation software market, by type, 2013 - 2024 (USD Million)
TABLE 53 Latin America biosimulation services market, by type, 2013 - 2024 (USD Million)
TABLE 54 Latin America biosimulation market, by application, 2013 - 2024 (USD Million)
TABLE 55 Latin America biosimulation market, by end-use, 2013 - 2024 (USD Million)
TABLE 56 Brazil biosimulation market, by product, 2013 - 2024 (USD Million)
TABLE 57 Brazil biosimulation software market, by type, 2013 - 2024 (USD Million)
TABLE 58 Brazil biosimulation services market, by type, 2013 - 2024 (USD Million)
TABLE 59 Brazil biosimulation market, by application, 2013 - 2024 (USD Million)
TABLE 60 Brazil biosimulation market, by end-use, 2013 - 2024 (USD Million)
TABLE 61 Mexico biosimulation market, by product, 2013 - 2024 (USD Million)
TABLE 62 Mexico biosimulation software market, by type, 2013 - 2024 (USD Million)
TABLE 63 Mexico biosimulation services market, by type, 2013 - 2024 (USD Million)
TABLE 64 Mexico biosimulation market, by application, 2013 - 2024 (USD Million)
TABLE 65 Mexico biosimulation market, by end-use, 2013 - 2024 (USD Million)
TABLE 66 MEA biosimulation market, by product, 2013 - 2024 (USD Million)
TABLE 67 MEA biosimulation software market, by type, 2013 - 2024 (USD Million)
TABLE 68 MEA biosimulation services market, by type, 2013 - 2024 (USD Million)
TABLE 69 MEA biosimulation market, by application, 2013 - 2024 (USD Million)
TABLE 70 MEA biosimulation market, by end-use, 2013 - 2024 (USD Million)
TABLE 71 South Africa biosimulation market, by product, 2013 - 2024 (USD Million)
TABLE 72 South Africa biosimulation software market, by type, 2013 - 2024 (USD Million)
TABLE 73 South Africa biosimulation services market, by type, 2013 - 2024 (USD Million)
TABLE 74 South Africa biosimulation market, by application, 2013 - 2024 (USD Million)
TABLE 75 South Africa biosimulation market, by end-use, 2013 - 2024 (USD Million)

List of Figures

FIG. 1 Market summary
FIG. 2 Market trends & outlook
FIG. 3 Market segmentation & scope
FIG. 4 Market driver relevance analysis (Current & future impact)
FIG. 5 Penetration & growth prospect mapping
FIG. 6 SWOT Analysis, By Factor (political & legal, economic and technological)
FIG. 7 Porter’s Five Forces Analysis
FIG. 8 Biosimulation market product outlook key takeaways
FIG. 9 Biosimulation market: Product movement analysis
FIG. 10 Global software market, 2013 - 2024 (USD Million)
FIG. 11 Global services market, 2013 - 2024 (USD Million)
FIG. 12 Global in-house services market, 2013 - 2024 (USD Million)
FIG. 13 Global contract services market, 2013 - 2024 (USD Million)
FIG. 14 Biosimulation market application outlook: Key takeaways
FIG. 15 Biosimulation market: Application movement analysis
FIG. 16 Global drug development market, 2013 - 2024 (USD Million)
FIG. 17 Global drug discovery market, 2013 - 2024 (USD Million)
FIG. 18 Global others market, 2013 - 2024 (USD Million)
FIG. 19 Regional market place: Key takeaways
FIG. 20 Regional outlook, 2015 & 2024
FIG. 21 Global pharmaceutical & biotechnological companies market, 2013 - 2024 (USD Million)
FIG. 22 Global CROs market, 2013 - 2024 (USD Million)
FIG. 23 Global regulatory authorities market, 2013 - 2024 (USD Million)
FIG. 24 Global research institutes market, 2013 - 2024 (USD Million)
FIG. 25 Regional market place: Key takeaways
FIG. 26 Regional outlook, 2015 & 2024
FIG. 27 North America biosimulation market, 2013 - 2024 (USD Million)
FIG. 28 U.S. biosimulation market, 2013 - 2024 (USD Million)
FIG. 29 Canada biosimulation market, 2013 - 2024 (USD Million)
FIG. 30 Europe biosimulation market, 2013 - 2024 (USD Million)
FIG. 31 Germany biosimulation market, 2013 - 2024 (USD Million)
FIG. 32 UK biosimulation market, 2013 - 2024 (USD Million)
FIG. 33 Asia Pacific biosimulation market, 2013 - 2024 (USD Million)
FIG. 34 Japan biosimulation market, 2013 - 2024 (USD Million)
FIG. 35 China biosimulation market, 2013 - 2024 (USD Million)
FIG. 36 India biosimulation market, 2013 - 2024 (USD Million)
FIG. 37 Latin America biosimulation market, 2013 - 2024 (USD Million)
FIG. 38 Brazil biosimulation market, 2013 - 2024 (USD Million)
FIG. 39 Mexico biosimulation market, 2013 - 2024 (USD Million)
FIG. 40 MEA biosimulation market, 2013 - 2024 (USD Million)
FIG. 41 South Africa biosimulation market, 2013 - 2024 (USD Million)
FIG. 42 Strategy framework
FIG. 43 Participant categorization